Mazzone, Elena Stacy
 Distribuzione geografica
Continente #
NA - Nord America 1.046
AS - Asia 1.035
EU - Europa 746
SA - Sud America 217
AF - Africa 29
OC - Oceania 1
Totale 3.074
Nazione #
US - Stati Uniti d'America 995
SG - Singapore 504
CN - Cina 263
IT - Italia 226
BR - Brasile 179
DE - Germania 95
SE - Svezia 88
FR - Francia 55
GB - Regno Unito 55
IE - Irlanda 48
VN - Vietnam 43
ID - Indonesia 40
IN - India 39
FI - Finlandia 33
RU - Federazione Russa 31
CA - Canada 30
HK - Hong Kong 29
PL - Polonia 27
KR - Corea 24
JP - Giappone 21
NL - Olanda 19
TR - Turchia 18
ES - Italia 13
AR - Argentina 11
ZA - Sudafrica 10
BD - Bangladesh 9
PK - Pakistan 9
EC - Ecuador 8
MX - Messico 8
PE - Perù 8
AT - Austria 6
CO - Colombia 6
IL - Israele 6
LT - Lituania 6
SA - Arabia Saudita 6
UA - Ucraina 6
DK - Danimarca 5
BG - Bulgaria 4
CH - Svizzera 4
CZ - Repubblica Ceca 4
EG - Egitto 4
IQ - Iraq 4
IR - Iran 4
PA - Panama 4
DZ - Algeria 3
JM - Giamaica 3
LV - Lettonia 3
UZ - Uzbekistan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
MA - Marocco 2
NG - Nigeria 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BY - Bielorussia 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HT - Haiti 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
MG - Madagascar 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 3.074
Città #
Singapore 265
Ashburn 185
Chandler 108
New York 83
Hefei 76
Los Angeles 46
Beijing 44
Dallas 42
Dublin 40
Jakarta 38
Munich 38
Rome 34
Milan 32
Hong Kong 27
Seoul 24
Chicago 21
Kent 20
São Paulo 20
Tokyo 20
Warsaw 20
Ho Chi Minh City 18
Santa Clara 18
Helsinki 17
Boston 16
Moscow 14
Nuremberg 14
Palermo 14
Frankfurt am Main 13
Turku 13
Chennai 11
Denver 11
London 11
Poplar 11
Atlanta 10
Düsseldorf 10
Hanoi 10
Marseille 10
Pune 10
Toronto 10
Stockholm 9
Buffalo 8
Houston 8
Johannesburg 8
Lima 8
Princeton 8
Ankara 7
Brooklyn 7
Manchester 7
San Mateo 7
Amsterdam 6
Columbus 6
Falkenstein 6
Florence 6
Montreal 6
Phoenix 6
San Francisco 6
Secaucus 6
Wilmington 6
Boardman 5
Brasília 5
Curitiba 5
Lauterbourg 5
Naples 5
Orem 5
Turin 5
Ancona 4
Edinburgh 4
Fairfield 4
Kiel 4
Mexico City 4
New Delhi 4
Quito 4
Shenzhen 4
Bern 3
Bremen 3
Brno 3
Bucaramanga 3
Busto Arsizio 3
City of London 3
Council Bluffs 3
Duque de Caxias 3
Faisalabad 3
Haiphong 3
Hangzhou 3
Harrisburg 3
Istanbul 3
Lappeenranta 3
Panama City 3
Riga 3
Rio de Janeiro 3
Riyadh 3
Salvador 3
Sofia 3
Taboão da Serra 3
Tashkent 3
Triggiano 3
Uberlândia 3
Vilnius 3
Volta Redonda 3
Wroclaw 3
Totale 1.703
Nome #
Performance of Upper Limb module for Duchenne muscular dystrophy 214
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 171
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 139
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 132
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 129
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 125
Our Experience on Temporal Bone Fractures: Retrospective Analysis of 141 Cases 116
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 111
Emergencies cards for neuromuscular disorders 1st Consensus Meeting from UILDM - Italian Muscular Dystrophy Association Workshop report 102
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 102
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 100
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 100
Clinical Variability in Spinal Muscular Atrophy Type III. 92
Revised upper limb module for spinal muscular atrophy: Development of a new module 91
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 81
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 80
Sleep disorders in spinal muscular atrophy 79
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 79
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 78
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA) 75
Old measures and new scores in spinal muscular atrophy patients 68
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 67
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 (PLoS ONE (2019) 14:6 (e0218683) DOI: 10.1371/journal.pone.0218683) 67
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 65
First international workshop on rehabilitation management and clinical outcome measures for spinal muscular atrophy 61
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0 60
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 59
Early neurodevelopmental assessment in Duchenne muscular dystrophy 57
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 55
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 53
Assessing upper limb function in nonambulant SMA patients: Development of a new module 45
Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy 39
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 39
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability 38
Daily salbutamol in young patients with SMA type II 37
Correction: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-Month changes 37
Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM 36
Reliability of the North Star Ambulatory Assessment in a multicentric setting 27
Totale 3.106
Categoria #
all - tutte 14.701
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.701


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 1 1 0
2021/202293 11 0 0 19 4 6 3 10 4 6 18 12
2022/2023359 19 30 26 44 30 59 17 34 51 12 20 17
2023/2024467 22 83 12 23 15 87 40 43 11 21 50 60
2024/2025852 22 15 82 25 60 53 47 34 82 69 209 154
2025/20261.333 267 68 177 321 470 30 0 0 0 0 0 0
Totale 3.106